Coherus BioSciences Inc (CHRS) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Coherus BioSciences Inc stock (CHRS) is currently trading at $1.71. Coherus BioSciences Inc PS ratio (Price-to-Sales) is 5.40. Analyst consensus price target for CHRS is $6.75. WallStSmart rates CHRS as Underperform.
- CHRS PE ratio analysis and historical PE chart
- CHRS PS ratio (Price-to-Sales) history and trend
- CHRS intrinsic value — DCF, Graham Number, EPV models
- CHRS stock price prediction 2025 2026 2027 2028 2029 2030
- CHRS fair value vs current price
- CHRS insider transactions and insider buying
- Is CHRS undervalued or overvalued?
- Coherus BioSciences Inc financial analysis — revenue, earnings, cash flow
- CHRS Piotroski F-Score and Altman Z-Score
- CHRS analyst price target and Smart Rating
Coherus BioSciences Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Coherus BioSciences Inc (CHRS) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in return on equity, revenue growth, profit margin. Concerns around market cap and operating margin. Mixed signals suggest waiting for clearer direction before acting.
Coherus BioSciences Inc (CHRS) Key Strengths (3)
Every $100 of shareholder equity generates $33 in profit
Revenue surging 64.90% year-over-year
Keeps $398 of every $100 in revenue as net profit
Supporting Valuation Data
Coherus BioSciences Inc (CHRS) Areas to Watch (6)
Losing money on operations
Earnings declining -75.50%, profits shrinking
Micro-cap company with very limited liquidity and high volatility
Premium valuation at 5.4x annual revenue
Premium pricing at 3.7x book value
Moderate institutional interest at 34.71%
Supporting Valuation Data
Coherus BioSciences Inc (CHRS) Detailed Analysis Report
Overall Assessment
This company scores 47/100 in our Smart Analysis, earning a D+ grade. Out of 9 metrics analyzed, 3 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 2.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Return on Equity, Revenue Growth, Profit Margin. Profitability is solid with Return on Equity at 33.10%, Profit Margin at 398.40%. Growth metrics are encouraging with Revenue Growth at 64.90%.
The Bear Case
The primary concerns are Operating Margin, EPS Growth, Market Cap. Some valuation metrics including Price/Sales (5.40), Price/Book (3.75) suggest expensive pricing. Growth concerns include EPS Growth at -75.50%, which may limit upside. Profitability pressure is visible in Operating Margin at -339.50%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Operating Margin improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 33.10% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 64.90% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Operating Margin and EPS Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CHRS Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CHRS's Price-to-Sales ratio of 5.40x trades at a deep discount to its historical average of 230.35x (45th percentile). The current valuation is 100% below its historical high of 1723.73x set in Aug 2019, and 1488% above its historical low of 0.34x in Jun 2025. Over the past 12 months, the PS ratio has expanded from ~0.4x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Coherus BioSciences Inc (CHRS) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Coherus BioSciences Inc is a strong growth company balancing expansion with improving profitability. Revenue reached 42M with 65% growth year-over-year. Profit margins are strong at 398.4%, reflecting pricing power and operational efficiency.
Key Findings
Revenue growing at 65% YoY, reaching 42M. This pace significantly outperforms most BIOTECHNOLOGY peers.
ROE of 33.1% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Free cash flow is -20M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
Earnings fell 76% YoY while revenue grew 65%. This gap usually reflects one-time items (tax benefits, write-offs) in the prior period, not an operational decline.
What to Watch Next
Growth sustainability: can Coherus BioSciences Inc maintain 65%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Coherus BioSciences Inc.
Bottom Line
Coherus BioSciences Inc offers an attractive blend of growth (65% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(6 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 10:09:46 AM
About Coherus BioSciences Inc(CHRS)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilars and immuno-oncology market primarily in the United States. The company is headquartered in Redwood City, California.